Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 17/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134880 | 0.93 | CSNK2A1 (0.43) | CSNK2A1PIM1CSNK2BPIM2PRKCI | |
| SCHEMBL10132255 | 0.87 | CSNK2A1 (0.48) | CSNK2A1PIM1CSNK2BPIM2 | |
| SCHEMBL10132272 | 0.83 | CSNK2A1 (0.44) | CSNK2A1 | |
| SCHEMBL10132264 | 0.82 | CSNK2A1 (0.43) | CSNK2A1 | |
| SCHEMBL10132314 | 0.80 | CSNK2A1 (0.43) | CSNK2A1PRKCI | |
| SCHEMBL13702784 | 0.80 | CSNK2A1 (0.57) | CSNK2A1PIM1CSNK2BPIM2PRKCI | |
| SCHEMBL1929478 | 0.78 | CSNK2A1 (0.71) | CSNK2A1 | |
| SCHEMBL10134993 | 0.78 | CSNK2A1 (0.55) | CSNK2A1PIM1CSNK2BPIM2PRKCI | |
| SCHEMBL10132164 | 0.78 | CSNK2A1 (0.68) | CSNK2A1 | |
| SCHEMBL10132296 | 0.78 | CSNK2A1 (0.55) | CSNK2A1CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885PIM1 1/4885CSNK2B 772/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885PIM1 1/4885CSNK2B 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.